Cargando…
Synthetic lethality in lung cancer and translation to clinical therapies
Lung cancer is a heterogeneous disease consisting of multiple histological subtypes each driven by unique genetic alterations. Despite the development of targeted therapies that inhibit the oncogenic mutations driving a subset of lung cancer cases, there is a paucity of effective treatments for the...
Autores principales: | Leung, Ada W. Y., de Silva, Tanya, Bally, Marcel B., Lockwood, William W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041331/ https://www.ncbi.nlm.nih.gov/pubmed/27686855 http://dx.doi.org/10.1186/s12943-016-0546-y |
Ejemplares similares
-
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation
por: Topatana, Win, et al.
Publicado: (2020) -
Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma
por: Unni, Arun M, et al.
Publicado: (2015) -
Sulfonation, an underexploited area: from skeletal development to infectious diseases and cancer
por: Leung, Ada W.Y., et al.
Publicado: (2016) -
The tumor therapy landscape of synthetic lethality
por: Zhang, Biyu, et al.
Publicado: (2021) -
Epigenetic synthetic lethality approaches in cancer therapy
por: Yang, Haoshen, et al.
Publicado: (2019)